Browse News
Filter News
Found 36,017 articles
-
U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
4/18/2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) ENTYVIO.
-
Red Biotechnology Market Size, CAGR, Trends, Report 2024 to 2033
4/18/2024
According to Vision Research Reports, the global red biotechnology market size was estimated at around USD 492.74 billion in 2023
-
Cancer Gene Therapy Industry is Rising Rapidly Up to USD 18.11 Bn by 2033
4/18/2024
The global cancer gene therapy market size was accounted for USD 2.95 billion in 2023 and it is increasing around USD 18.11 billion by 2033
-
Immutep Appoints Leading Research Institute to Conduct First-in-Human Phase I Study of IMP761
4/18/2024
Immutep Limited today announces it has entered into an agreement with the Centre for Human Drug Research (CHDR), a world-class institute in Leiden, the Netherlands specializing in cutting-edge early-stage clinical drug research, to perform a first-in-human clinical study of IMP761.
-
Immix Biopharma on Track to Dose NXC-201 Patients in United States
4/18/2024
Immix Biopharma, Inc. (Nasdaq: IMMX) (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and other autoimmune diseases, today announced that Immix Biopharma is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
-
Ferring Pharmaceuticals and SK Pharmteco Enter into Commercial Gene Therapy Manufacturing Deal
4/18/2024
Ferring Pharmaceuticals and SK pharmteco today announced an agreement to scale up commercial manufacturing capacity for the drug substance of Ferring’s intravesical non-replicating gene therapy ADSTILADRIN (nadofaragene firadenovec-vncg) for ensuring long-term future supply.
-
Nexcella, an Immix Biopharma Subsidiary, on Track to Dose NXC-201 Patients in United States
4/18/2024
Nexcella today announced that it is on track to dose NXC-201 patients in the U.S. with no change in patient enrollment timing.
-
Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
4/18/2024
Revive Therapeutics Ltd. announced today that the U.S. Food & Drug Administration (“FDA”) has accepted the Company’s meeting request for the Revive LC POC Lateral Flow Test Kit.
-
Quebec's INESSS recommends BEYFORTUS for the prevention of RSV for all infants 8 months of age and younger(1)
4/18/2024
BEYFORTUS ® (nirsevimab) is the first long-acting antibody approved in Canada for the prevention of Respiratory Syncytial Virus (RSV) lower respiratory tract disease in neonates and infants through their first RSV season.
-
Biotricity Launches Major Cardiac Monitoring Pilot Program in a Hospital System Comprised of 9 Hospitals and 10 Clinics
4/18/2024
Biotricity Inc. announces a groundbreaking cardiac monitoring pilot program with a prestigious hospital group spanning 9 hospitals and 10 clinics.
-
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer
4/18/2024
Lumicell, Inc. today announced the U.S. Food & Drug Administration (FDA) approved the company’s New Drug Application (NDA) for its LUMISIGHT™ (pegulicianine) optical imaging agent and its Premarket Approval (PMA) application for Lumicell™ Direct Visualization System (DVS), together referred to as LumiSystem™.
-
Coya Therapeutics to Participate in the 3rd Annual ALS Drug Development Summit
4/18/2024
Coya Therapeutics, Inc. (Nasdaq: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces that President and Chief Medical Officer Dr. Fred Grossman, D.O., FAPA will participate in the 3rd Annual ALS Drug Development Summit being held May 21 – 23 at the Hyatt Regency in Boston.
-
Lumos Pharma Announces Abstracts Accepted for Presentation at Upcoming Medical Meetings
4/18/2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced today that abstracts reviewing data from its Phase 2 OraGrowtH210 and OraGrowtH212 Trials will be presented at several upcoming medical meetings in the US and Europe.
-
NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting
4/18/2024
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense") announces the presentation of data from the Company's PARADIGM Phase 2b study of PrimeC during an Emerging Science session (equivalent to Late Breaker) at the American Academy of Neurology Annual Meeting, which validates the previously announced topline data.
-
At this week’s American Academy of Neurology annual meeting, Amylyx provided additional data from its Phase III amyotrophic lateral sclerosis study showing the full extent of Relyvrio’s failure.
-
After withdrawing ALS drug Relyvrio from the U.S. and Canadian markets and laying off 70% of its workforce, the Cambridge, Mass.–based biopharma got a much-needed win in Wolfram syndrome.
-
Amylyx looks to the future after Relyvrio withdrawal, ADCs continue to attract investment and the drug shortage persists in the U.S.
-
Follow along as BioSpace keeps you up-to-date on the latest pharma and biotech layoffs.
-
Biopharmaceutical Fermentation Market Size Expected to Reach USD 16.03 Billion to 2031
4/17/2024
Global Biopharmaceutical Fermentation Market is valued at US$ 10.17 Bn in 2023, and it is expected to reach US$ 16.03 Bn by 2031, with a CAGR of 6.11% during the forecast period of 2024-2031.
-
Cell-Free RNA Isolation and Extraction Kits Market Reach USD123.94 Million by 2031
4/17/2024
Global Cell-Free RNA Isolation & Extraction Kits Market is valued at US$ 41.55 Mn in 2023, and it is expected to reach US$ 123.94 Mn by 2031, with a CAGR of 14.90% during the forecast period of 2024-2031.